A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 210 participants.

Also called NCT06568471

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 210 participants (planned count) (from the registry)
Sponsor
Hasten Biopharmaceutical Co., Ltd. (from the registry)
Registry
  • NCT NCT06568471
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06568471. Randomized; triple masking; primary purpose treatment. Start 2024-11-16 (actual); primary completion 2026-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
Condition
Hypercholesterolemia
Condition
Dyslipidemias
Condition
Primary Hypercholesterolemia
Condition
Heterozygous Familial Hypercholesterolemia
Condition
Hyperlipidemia; Mixed
Condition
Metabolic Disease
Condition
ASCVD
Intervention (Drug)
Lerodalcibep
Intervention (Drug)
matching placebo
Lead sponsor
Hasten Biopharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06568471
Content hash
add151570a74c68f93755845122c5c92cd69b0683bdf4d7b86bf5ddef390ae45